Imran Mohmmad, Ahmad Mohammad Naiyaz, Dasgupta Arunava, Rana Preeti, Srinivas Nanduri, Chopra Sidharth
Division of Microbiology, CSIR-Central Drug Research Institute, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow, 226031, India.
Academy of Scientific & Innovative Research, Ghaziabad, 201002, India.
Future Med Chem. 2022 Aug;14(15):1133-1148. doi: 10.4155/fmc-2022-0029. Epub 2022 Jul 21.
Antimicrobial resistance (AMR), which is a major challenge for global healthcare, emerging because of several reasons including overpopulation, increased global migration and selection pressure due to enhanced use of antibiotics. Antibiotics are the widely used therapeutic options to combat infectious diseases; however, unfortunately, inadequate and irregular antibiotic courses are also major contributing factors in the emergence of AMR. Additionally, persistent failure to develop and commercialize new antibiotics has created the scarcity of effective anti-infective drugs. Thus, there is an urgent need for a new class of antimicrobials and other novel approaches to curb the menace of AMR. Besides the conventional approaches, some novel approaches such as the use of antimicrobial peptides, bacteriophages, immunomodulation, host-directed therapy and antibodies have shown really promising potentials.
抗菌耐药性(AMR)是全球医疗保健面临的一项重大挑战,其出现的原因有多种,包括人口过剩、全球移民增加以及抗生素使用增加带来的选择压力。抗生素是治疗传染病广泛使用的选择;然而,不幸的是,抗生素疗程不足和不规律也是抗菌耐药性出现的主要促成因素。此外,新抗生素研发和商业化的持续失败导致了有效抗感染药物的短缺。因此,迫切需要一类新型抗菌药物和其他新方法来遏制抗菌耐药性的威胁。除了传统方法外,一些新方法,如使用抗菌肽、噬菌体、免疫调节、宿主导向疗法和抗体,已显示出非常有前景的潜力。